Denali Therapeutics (NASDAQ:DNLI) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $95.00 target price on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ FY2027 earnings at $1.99 EPS and FY2028 earnings at $4.48 EPS.

A number of other equities research analysts have also recently issued reports on the stock. Wedbush reissued an outperform rating and issued a $31.00 target price on shares of Denali Therapeutics in a research report on Wednesday, February 28th. Stifel Nicolaus lowered their target price on Denali Therapeutics from $26.00 to $22.00 and set a hold rating for the company in a research note on Wednesday. UBS Group cut their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a buy rating on the stock in a research report on Tuesday, April 9th. Finally, The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a buy rating for the company in a report on Thursday, February 29th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $40.22.

Denali Therapeutics Trading Down 0.8 %

Shares of NASDAQ:DNLI traded down $0.16 on Wednesday, hitting $18.74. The company had a trading volume of 75,423 shares, compared to its average volume of 1,167,723. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of -17.50 and a beta of 1.39. The stock has a 50 day moving average price of $18.80 and a 200 day moving average price of $18.84. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the prior year, the business earned ($0.80) EPS. Sell-side analysts anticipate that Denali Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 92,500 shares of Denali Therapeutics stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the transaction, the director now directly owns 47,341 shares of the company’s stock, valued at $970,490.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the transaction, the director now owns 47,341 shares in the company, valued at $970,490.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Carole Ho sold 2,784 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $48,135.36. Following the sale, the insider now owns 145,010 shares of the company’s stock, valued at $2,507,222.90. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock worth $2,218,802 over the last three months. Company insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNLI. Norges Bank bought a new stake in shares of Denali Therapeutics in the 4th quarter valued at $24,736,000. Braidwell LP bought a new stake in Denali Therapeutics in the fourth quarter valued at $9,910,000. Principal Financial Group Inc. raised its holdings in shares of Denali Therapeutics by 57.9% during the fourth quarter. Principal Financial Group Inc. now owns 1,073,704 shares of the company’s stock valued at $23,042,000 after purchasing an additional 393,626 shares during the period. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 3.5% during the 3rd quarter. Vanguard Group Inc. now owns 10,597,781 shares of the company’s stock worth $218,632,000 after purchasing an additional 354,798 shares in the last quarter. Finally, abrdn plc acquired a new stake in shares of Denali Therapeutics in the 4th quarter valued at about $6,971,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.